El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
AngioDynamics Inc
Cerrado
SectorSalud
10.94 1.67
Resumen
Variación precio
24h
Mínimo
10.47
Máximo
11.17
Ingresos | 4.6M -6.4M |
|---|---|
Ventas | 3.7M 79M |
Margen de beneficio | -7.994 |
Empleados | 675 |
EBITDA | 4.4M -436K |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 meses | +79.31% upside |
Próximas Ganancias | 1 abr 2026 |
|---|
Capitalización de Mercado | -101M 444M |
|---|---|
Apertura anterior | 9.27 |
Cierre anterior | 10.94 |
Noticias sobre sentimiento de mercado
By Acuity
28%
72%
55 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Bearish Evidence
AngioDynamics Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
AngioDynamics Inc Esperado
Precio Objetivo
By TipRanks
79.31% repunte
Estimación a 12 meses
Media 19.33 USD 79.31%
Máximo 24 USD
Mínimo 16 USD
De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AngioDynamics Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
55 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Coyuntura alcista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por encima de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de AngioDynamics Inc
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
Live chat